Yatiri Bio Inc.

Yatiri Bio Inc. receives $100k in Amazon Web Services (AWS) cloud credits from NVIDIA Inception program! We are extremely grateful to the NVIDIA Inception program and Amazon Web Services (AWS) for $100k in cloud credits. These credits will help drive the next generation of our deep-learning models that predict patient outcomes in AML and Ovarian cancer. Having this level of GPU computational power available allows us to explore the integration of large public ‘omics datasets with our vast internal data, further optimizing our knowledge maps to improve therapeutic positioning and patient outcomes. Please reach out to us if you are interested in identifying patients that may be sensitive to your therapeutic, or if you would like to collaborate on advancements in precision medicine. #nvidia, #NVIDIAInception, #ai #yatiribio, #AML, #OvarianCancer

The 3rd Quarterly San Diego Proteomics Happy Hour is in the books and it was another great evening. It was nice to see so many proteomics scientists coming together to talk shop, enjoy refreshments, and share ideas across academia and industry. A huge thank you goes out to Lisa Jones for giving such an insightful talk on the potential for structural proteomics in vivo including some of her latest research with FPOP Also, we would like to thank Thermo Fisher Scientific, Seer, and Founders Corner VC for sponsoring this event. We look forward to seeing everyone next quarter for more engaging discussions. If you are interested in this event, please contact us.

Yatiri Bio is excited to host another San Diego Proteomics Happy Hour. We are honored to feature Lisa Jones, a UCSD Professor and leader in the development of in-vivo foot printing. Professor Jones will be presenting on "Structural Biology Across the Proteome: An In-Cell Mass Spectrometry-Based Foot printing Method". Please join us on Thursday, November 7th, from 4:00 PM to 7:00 PM for drinks and appetizers at 2010 Jimmy Durante Blvd. in Del Mar, California. We look forward to seeing you there! Yatiri Bio is pleased to host this event with support from Thermo Fisher Scientific, Seer, and FCVC.

We are thrilled to have Carl join our strategic advisory board. I look forward to working with him as we advance our predictive oncology models.

Yatiri Bio is pleased to announce the appointment of Dr. Carl Goldfischer as a scientific advisory board member. Dr. Goldfischer has 30 years of investment, operational and board service in the biotechnology industry.  We look forward to working with and strategizing with Dr. Goldfischer as we commercialize our AML and Ovarian Cancer platform with pharma partnerships. For more information about this announcement, please see https://lnkd.in/gjFe38CV.

The 2nd Quarterly San Diego Proteomics Happy Hour was a great success! We were glad to see so many proteomics practitioners in the San Diego area coming together to talk shop, enjoy refreshments, and share ideas. A big thank you goes out to Professor John Yates for giving an informative and excellent talk. Also, we would like to thank Thermo Fisher Scientific and Founders Corner VC for sponsoring this event. We look forward to seeing everyone at the next event in October. If you are interested in this event, please contact us. 

Yatiri Bio is proud to host it's 2nd quarterly San Diego Proteomics Happy Hour. Our mission is to bring together those that work on all aspects of proteomics for an open and educational discussion. We are honored to have John Yates III, Earnst W. Hahn professor at TSRI, and president of HUPO give a talk titled “How A Single Mutation in CFTR Causes the Systemic Disease Cystic Fibrosis: Interactions, PTMs, And Structure” to stimulate the conversation. Please join us on Thursday July 11th from 4:30-7:30 pm for drinks, appetizers, and a lively talk by using the below link to RSVP to this event. https://lnkd.in/g8gHpr9J Thank you to Thermo Fisher Scientific and FCVC for sponsoring this event.  

Yatiri Bio Inc. has joined NVIDIA Inception , a program that nurtures startups revolutionizing industries with technological advancements. Yatiri Bio approaches oncology with a whole system perspective, incorporating patient data, organoids, proteomics, and machine learning to create models predictive of patient outcomes. Our models create a molecularly defined patient landscape with testable systems embedded within this landscape, revolutionizing drug discovery. Yatiri Bio models are used by the pharmaceutical industry to identify patients sensitive to their therapeutics, increase the likelihood of clinical approval, expand therapeutic markets, and identify novel therapeutic targets with well-defined patient selection criteria. Joining NVIDIA Inception will help Yatiri Bio to optimize and scale our deep learning algorithms that drive our predictive models with access to training and GPU cloud credits.   The program will also offer Yatiri Bio the opportunity to collaborate with industry-leading experts and other AI-driven organizations. Dr. Pilgrim Jackson, CEO of Yatiri Bio stated that “The NVIDIA Inception Program is a game changer that allows us to significantly expand our AI/ML capabilities to develop accurate model systems across multiple indications. The end result is that our technology can bring efficacious therapies to the patients that need them. We are fortunate that such programs are available that can further enhance our product offering.”     NVIDIA Inception helps startups during critical stages of product development, prototyping and deployment. Every Inception member gets a custom set of ongoing benefits, such as NVIDIA Deep Learning Institute credits, preferred pricing on NVIDIA hardware and software, and technological assistance, which provides startups with the fundamental tools to help them grow. #NVIDIAInception, #NVIDIA, #ai, #YatiriBio,

We are excited to announce that we were selected as 1 of 6 finalists for the San Diego Angel Conference Fund VI. This competition shines a spotlight on innovative San Diego-based companies like ours. Come support and meet our CEO Pilgrim Jackson on Thursday, May 9th as he makes his pitch! #SanDeigoConference #Startups #InnovateSD

We are excited to announce that Michael Kamdar, former CEO and President of Molecular Assemblies, will join Yatiri Bio Inc.’s strategic advisory board. Mike has a very successful track record of helping businesses raise money, scale operations, and cultivate growth. Mike has a long list of accomplishments including having negotiated over $1B in business deals and raised more than $450M from venture firms and public markets. His vast business experience and scientific knowledge are also showcased in the numerous companies that he has led and co-founded. We look forward to working closely with Mike as we raise our Series A financing and fully commercialize our AML platform with pharma partnerships. For more information about this announcement, please see https://lnkd.in/gNbpUxS8